Loading organizations...
Biogenesis is a technology company operating through the domain mybiogenesis.com, though its specific headquarters and primary geographic base of operations remain undisclosed in public records. The organization maintains a limited public profile regarding its core products, software services, and underlying business model, operating without publicly detailing its target sectors or customer demographics. Consequently, specific operational metrics typically associated with technology startups, such as total venture funding raised, current enterprise valuation, active user counts, or total employee headcount, are not publicly available. Furthermore, the company has not disclosed recognizable names related to its corporate ecosystem, meaning there is no public information regarding its lead institutional investors, strategic enterprise customers, or corporate partnerships. Details regarding the exact founding year and the identities of the original founders of this technology entity remain unverified and absent from standard corporate databases.
Biogenesis has raised $250K across 1 funding round.
Biogenesis has raised $250K in total across 1 funding round.
Biogenesis has raised $250K across 1 funding round. Most recently, it raised $250K Seed in October 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2023 | $250K Seed | — | Alumni Ventures, BEN Taft's Genius Ventures, General Catalyst, Kepler Operator’s Fund, Afraj Gill, Bianca Ambrosini | Announced |
BioGenesis Tech, Inc. is a patient-facing mobile app that integrates electronic medical records (EMR), genomic sequencing, nutritional and symptomatic data, and wearables to deliver AI-driven diagnostic and prognostic feedback based on evidence-based medicine.[1] Founded in 2022 in South San Francisco, California, it primarily targets expecting mothers with high-risk pregnancies—a underserved group despite their high needs—and has raised early funding from UCSC while building traction in healthcare AI, consumer genomics, and patient health records.[1]
The app solves the problem of fragmented health data by compiling comprehensive inputs into actionable insights, serving patients directly rather than healthcare providers. Early momentum includes a focused team and investor backing, positioning it for growth in personalized medicine amid rising demand for proactive maternal health tools.[1]
BioGenesis Tech, Inc. was founded in 2022 by Edward Fisher and Martin Michalko in South San Francisco.[1] Edward Fisher, with a B.A. in Economics & Data/Life Science from UCSC, shifted from clinical hematology pursuits and investment banking (including a summer analyst role at J.P. Morgan Chase) to entrepreneurship in medicine.[1] Martin Michalko, the CTO, is a scientist and MLOps engineer passionate about data science, biology, and medicine.[1]
The idea emerged from recognizing gaps in patient-centric health tech, particularly for high-risk pregnancies, where few solutions aggregate diverse data sources like EMRs, genomics, wearables, and symptoms. Early traction came via UCSC investment and a lean team focused on this niche, marking a pivotal shift toward AI-enabled personal health management.[1]
BioGenesis rides the wave of AI-powered personalized medicine and digital health for maternal care, where trends like wearable adoption and genomic accessibility are exploding amid post-pandemic focus on preventive care.[1] Timing is ideal: high-risk pregnancies affect millions globally, yet patient tools lag behind provider-centric systems, amplified by market forces like rising fertility tech investments and data privacy regulations favoring secure, consumer apps.
It influences the ecosystem by pioneering direct-to-patient AI aggregation, potentially accelerating adoption of multi-omics health platforms and inspiring similar tools for chronic conditions, while contributing to broader equity in underserved health segments like maternal health.[1]
BioGenesis is poised to scale its app through partnerships with wearables giants and EMR providers, expanding beyond maternal health into general consumer genomics as AI models mature.[1] Trends like real-world evidence integration and edge AI on devices will shape its path, potentially evolving it into a full-stack personal health OS with global reach. Its niche entry could amplify influence, humanizing tech for vulnerable patients and setting a benchmark for data-driven diagnostics in an increasingly proactive healthcare landscape—echoing its core mission to deliver comprehensive, life-impacting health insights.[1]
Biogenesis has raised $250K in total across 1 funding round.
Biogenesis's investors include Alumni Ventures, Ben Taft's Genius Ventures, General Catalyst, Kepler Operator’s Fund, Afraj Gill, Bianca Ambrosini.
